%0 Journal Article
%A Oubari, Sara
%A Hegenbart, Ute
%A Schoder, Renate
%A Steinhardt, Maximilian
%A Papathanasiou, Maria
%A Rassaf, Tienush
%A Thimm, Andreas
%A Hagenacker, Tim
%A Naser, Eyad
%A Duhrsen, Ulrich
%A Reinhardt, Hans C
%A Kortum, Martin
%A Agis, Hermine
%A Schonland, Stefan
%A Carpinteiro, Alexander
%T Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
%J Haematologica
%V 109
%N 1
%@ 0390-6078
%C Pavia
%I Ferrata Storti Foundation
%M DKFZ-2023-01402
%P 220-230
%D 2024
%Z 2024 Jan 1;109(1):220-230
%X Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis remains challenging, and prognosis remains very poor. Mayo IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with bortezomib-cyclophosphamide-dexamethasone. This retrospective, multicenter study evaluates the addition of daratumumab to the first-line therapy in patients with newly diagnosed stage IIIb AL amyloidosis. In total, data from 119 consecutive patients were analyzed, 27 patients received an upfront treatment including daratumumab, 63 a bortezomib-based regimen without daratumumab, 8 received therapies other than daratumumab or bortezomib and 21 pretreated patients or deceased prior to treatment were excluded. In the daratumumab group, median overall survival was not reached after a median follow-up time of 14.5 months, while it was significantly worse in the bortezomib- and the otherwise treated group (6.6 and 2.2 months, respectively) (p=0.002). Overall hematologic response rate at 2 and 6 months was better in the daratumumab compared to the bortezomib group (59
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37439344
%R 10.3324/haematol.2023.283325
%U https://inrepo02.dkfz.de/record/277489